Swedish Orphan Biovitrum stock: fair value
SOBI.STThe fair value of Swedish Orphan Biovitrum under our model is $67.22, the price is 27% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $51.71 and expensive above $96.03 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $66.96 (cash-flow model) and $67.47 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $61.35, at 6.2% it would be $76.04.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (35.7).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 2.2%. Discounted at 7.2% (floor: government bond yield 2.2% plus 5 percentage points, since beta 1.1 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $66.96 per share: free cash flow for the next ten years, each year discounted to today at 7.2%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 7.2%) |
|---|---|---|---|---|
| 2026 | $749.12M | extrapolated at 26.6% | 0.9330 | $698.94M |
| 2027 | $893.49M | extrapolated at 19.3% | 0.8705 | $777.79M |
| 2028 | $1.02B | extrapolated at 14.1% | 0.8122 | $828.33M |
| 2029 | $1.13B | extrapolated at 10.6% | 0.7578 | $854.42M |
| 2030 | $1.22B | extrapolated at 8.0% | 0.7070 | $861.29M |
| 2031 | $1.29B | extrapolated at 6.3% | 0.6597 | $854.09M |
| 2032 | $1.36B | extrapolated at 5.1% | 0.6155 | $837.14M |
| 2033 | $1.42B | extrapolated at 4.2% | 0.5742 | $813.79M |
| 2034 | $1.47B | extrapolated at 3.6% | 0.5358 | $786.52M |
| 2035 | $1.51B | extrapolated at 3.2% | 0.4999 | $757.06M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $8.07B |
| Terminal value: cash flow 2035 × (1 + 2.2%) / (7.2% − 2.2%) | $30.95B |
| Present value of terminal value (× 0.4999) | $15.47B |
| Equity value (sum plus present value of terminal value) | $23.54B |
| Shares (diluted) | 351.54M |
| Value per share (equity value divided by shares) | $66.96 |
| Earnings per share, last twelve months | $1.89 |
| × 35.7 (industry P/E) | $67.47 |
| Fair value (average of both parts) | $67.22 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.